Drug Type Small molecule drug |
Synonyms GSK 705498, GSK-705498 |
Target |
Action antagonists |
Mechanism TRPV1 antagonists(Vanilloid receptor antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Molecular FormulaC17H16BrF3N4O |
InChIKeyJYILLRHXRVTRSH-GFCCVEGCSA-N |
CAS Registry501951-42-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Rhinitis, Allergic | Phase 2 | Austria | 14 Apr 2011 | |
Chronic cough | Phase 2 | United Kingdom | 01 Apr 2011 | |
Rhinitis | Phase 2 | United Kingdom | 01 Apr 2011 | |
Rhinitis, Allergic, Perennial | Phase 2 | Netherlands | 01 Dec 2009 | |
Hypersensitivity | Phase 2 | United Kingdom | 26 Jan 2007 | |
Irritable Bowel Syndrome | Phase 2 | United Kingdom | 26 Jan 2007 | |
Paroxysmal Extreme Pain Disorder | Phase 2 | United Kingdom | 26 Jan 2007 | |
Acute migraine | Phase 2 | Australia | 01 Jan 2006 | |
Acute migraine | Phase 2 | Canada | 01 Jan 2006 | |
Acute migraine | Phase 2 | Netherlands | 01 Jan 2006 |
Phase 2 | 145 | Placebo (Placebo) | wjymwtmiwa(ziiqrjadtv) = lxgqkczjrk ptsdjmciom (eipjxnafjx, 22.474) View more | - | 28 Jan 2019 | ||
(SB705498 400 mg) | wjymwtmiwa(ziiqrjadtv) = cdnnrlagrf ptsdjmciom (eipjxnafjx, 26.076) View more | ||||||
Phase 2 | 40 | Placebo | ejlahbxkpv(wanezmqbvz) = vfyexcnifs fyrwxwkvav (afnctqifve, 0.259) View more | - | 29 Jan 2018 | ||
Phase 1 | - | 16 | SB705498 3% topical formulation | ckbzlqezpp(rksfpunger) = vjepkxoflx xaptrmolbv (bspmwlkbat ) | - | 01 Jan 2014 | |
Placebo | ckbzlqezpp(rksfpunger) = ltxuoibiod xaptrmolbv (bspmwlkbat ) | ||||||
Not Applicable | 70 | SB-705498 12 mg plus fluticasone propionate 200 μg | - | Negative | 01 Jul 2013 | ||
Fluticasone propionate 200 μg |